Brief: BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
22/10/2025 12:37
Oct 22 (Reuters) - Briacell Therapeutics Corp BCT.TO: BRIACELL RECEIVES POSITIVE RECOMMENDATION FROM DATA SAFETY MONITORING BOARD (DSMB) FOR PHASE 3 STUDY IN METASTATIC BREAST CANCER BRIACELL THERAPEUTICS CORP - PHASE 3 STUDY UNDER FDA FAST TRACK DESIGNATION BEING CONDUCTED BRIACELL THERAPEUTICS CORP: POST REVIEW, DSMB RAISED NO SAFETY CONCERNS & RECOMMENDED STUDY CONTINUE WITHOUT MODIFICATIONS Source text: ID:nGNXbLCGNb Further company coverage: BCT.TO ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study